SII-PNI Score: Immune-Nutritional Biomarker for Gastric Cancer Immunotherapy Outcomes

276 records of locally advanced gastric cancer patients receiving neoadjuvant PD-1/PD-L1 inhibitor-based therapy from January 2019 to December 2021. The dataset, authored by Fang Li and shared under CC-BY-4.0, contains a combined Systemic Immune-Inflammation Index and Prognostic Nutritional Index (SII-PNI) score used to predict treatment efficacy and adverse events. The SII-PNI score demonstrated an AUC of 0.750 for predicting immunotherapy response.

Use Cases

• Predicting objective response rates to neoadjuvant immunotherapy based on SII-PNI score.
• Modeling disease-free and overall survival risk based on the SII-PNI score and other clinical factors.
• Stratifying patients for risk of severe immune-related adverse events (Grade 3-4) using the SII-PNI score.
• Comparing the predictive accuracy of the SII-PNI score against traditional biomarkers like PD-L1 CPS and Tumor Mutational Burden.

Strengths

• Dataset includes 276 patient records with defined clinical endpoints (DFS, OS, tumor response, irAE incidence).
• The SII-PNI score is validated with specific cut-off values (SII: 736.2, PNI: 48.5) and statistical performance metrics (AUC=0.750).
• Multivariate Cox analysis provides hazard ratios for recurrence (HR=3.45) and mortality (HR=3.15) associated with the high-risk score.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data is from a single retrospective study (January 2019–December 2021) and may reflect inherent temporal and source bias.

Provenance

Source

Fang Li via figshare.

Collection Method

Retrospective analysis of patient records and blood samples collected within 7 days before treatment initiation.

Time Range

January 2019 to December 2021.

Freshness

Last updated 2026-04-30 04:21:12; freshness should be verified.